New China Life Insurance Company Ltd. increases its shareholding in AVICHINA (02357) by 31 million shares at approximately HK$3.08 per share.
Following the increase, the latest shareholding is approximately 373 million shares, with the latest shareholding percentage at 6.01%.
The latest data from the Hong Kong Stock Exchange shows that on September 29, New China Life Insurance Company Ltd. increased its shareholding in AVICHINA (02357) by 31 million shares at HK$3.078 per share, for a total amount of approximately HK$95.418 million. After the increase, its latest shareholding stands at approximately 373 million shares, with its latest shareholding percentage at 6.01%.
This transaction involves a related party: New China Asset Management Co., Ltd.
Supplementary information: Pursuant to an investment management agreement between New China Asset Management Co., Ltd. ("NCAM") and New China Life Insurance Company Ltd. ("NCLI"), NCAM provides investment management and consulting services for NCLI's assets. On 29 September 2026, NCAM acquired 31,000,000 H shares of the listed corporation on-market, increasing its long position from 342,213,000 H shares (5.51%) to 373,213,000 H shares (6.01%). The shares are held as investment manager (capacity code 2102).
Related Articles

HK Stock Market Move | Innovative drug concept stocks retreated. InnoCare Pharma (09969) fell over 8%, REMEGEN (09995) dropped nearly 6%.

Goldman Sachs: Macau September gaming revenue down 1% year-on-year, in line with expectations; expects stable third-quarter EBITDA

HK Stock Market Move | BOYAA (00434) rises over 4%; Bitcoin briefly breaks above $86,000; Citi sees target price as high as $113,000.
HK Stock Market Move | Innovative drug concept stocks retreated. InnoCare Pharma (09969) fell over 8%, REMEGEN (09995) dropped nearly 6%.

Goldman Sachs: Macau September gaming revenue down 1% year-on-year, in line with expectations; expects stable third-quarter EBITDA

HK Stock Market Move | BOYAA (00434) rises over 4%; Bitcoin briefly breaks above $86,000; Citi sees target price as high as $113,000.






